Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

Exclusion Criteria

• •WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least one month (4 weeks) before and for at least 1 month (4 weeks) after the last dose of study medication.
• •WOCBP using a prohibited contraceptive method (Not applicable for this study).
• •Women who are pregnant or breastfeeding.
• •Women with a positive pregnancy test at enrollment or prior to administration of study medication.
• •Men whose sexual partners are WOCBP, who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least one month (4 weeks) after completion of study medication.
• •A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.
• •Known pleural effusion at baseline.
• •Uncontrolled or significant cardiovascular disease
• •History of significant bleeding disorder unrelated to CML
• •Prior chemotherapy for peripheral stem cell mobilization. (Prior collection of un-mobilized peripheral blood stem cells is permitted).
• •Prior or concurrent malignancy
• •Evidence of digestive dysfunction that would prevent administration of study therapy by mouth
• •Uncontrolled diabetes